chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory syncytial virus test negative, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: I was very congested, no fever, I was not achy, no vomiting, I did not test positive with a home test. I went to the doctor to get something for my congestion, it was mostly bronchial congestion. At the doctor's office they tested me for COVID-19, Influenza, RSV, the COVID -19 test did come back positive. I was not prescribed the antiviral. I was on an antibiotic as I had just come home from the hospital and was on antibiotics. It did take me two weeks to recover from having CVOID-19.
Age: 36.0
Sex: F
Vaccine: TDAP
Symptoms: Expired product administered
Clinical narrative: Inadvertently administered expired Tdap
Sex: U
Vaccine: COVID19
Symptoms: Blood calcium increased, Blood parathyroid hormone increased, Hyperparathyroidism
Clinical narrative: I believe it caused a high calcium level after receiving the vaccine.  My calcium went up to 11.0 on Dec. 19, 2022 and my PTH went up to. 96.   In February I was diagonsed with hyperparathyroidism. Never had a high calciuym before and now my calcium is backto normal on two occasions.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Acute respiratory failure, Aortic aneurysm, Atrial fibrillation, Coagulopathy
Clinical narrative: Pfizer vaccine was administered outside of faclity- reported by patient- ? NO LOT NUMBER WERE SUPPLIED ---------------------------------------------------------------------------------------------------------------------------------- COAGULOPATHY, UNSPECIFIED TYPE 12/17/2022 ATRIAL FIBRILLATION, PAROXYSMAL ACUTE NON ST ELEVATION MI 12/18/2022 ATRIAL FIBRILLATION, PAROXYSMAL ACUTE MI 12/17/2022 ATRIAL FIBRILLATION, PAROXYSMAL ACUTE RESPIRATORY FAILURE 12/17/2022 ATRIAL FIBRILLATION, PAROXYSMAL COAGULOPATHY, UNSPECIFIED TYPE 12/17/2022 ACUTE NON ST ELEVATION MI    ASCENDING THORACIC AORTIC ANEURYSM ACUTE NON ST ELEVATION MI 12/18/2022 ACUTE NON ST ELEVATION MI    ASCENDING THORACIC AORTIC ANEURYSM ACUTE MI 12/17/2022 ACUTE NON ST ELEVATION MI    ASCENDING THORACIC AORTIC ANEURYSM ACUTE RESPIRATORY FAILURE 12/17/2022 ACUTE NON ST ELEVATION MI    ASCENDING THORACIC AORTIC ANEURYSM
Age: 4.0
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event
Clinical narrative: NO ADVERSE EVENT
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Dementia, Epilepsy, Hypoglycaemia, Mental status changes
Clinical narrative: ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/27/2022 UNSPECIFIED DEMENTIA, UNSPECIFIED SEVERITY, WO BEHAVIORAL DISTURBANCE  HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/27/2022 UNSPECIFIED DEMENTIA, UNSPECIFIED SEVERITY, WO BEHAVIORAL DISTURBANCE  ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/27/2022 EPILEPSY, UNSPECIFIED  HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/27/2022 EPILEPSY, UNSPECIFIED  ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/27/2022 HYPOGLYCEMIA  HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/27/2022 HYPOGLYCEMIA  ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/27/2022 ALTERED MENTAL STATUS, UNSPECIFIED  HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/27/2022 ALTERED MENTAL STATUS, UNSPECIFIED
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory failure
Clinical narrative: ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/27/2022 UNSPECIFIED DEMENTIA, UNSPECIFIED SEVERITY, WO BEHAVIORAL DISTURBANCE  HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/27/2022 UNSPECIFIED DEMENTIA, UNSPECIFIED SEVERITY, WO BEHAVIORAL DISTURBANCE  ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/27/2022 EPILEPSY, UNSPECIFIED  HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/27/2022 EPILEPSY, UNSPECIFIED  ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/27/2022 HYPOGLYCEMIA  HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/27/2022 HYPOGLYCEMIA  ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/27/2022 ALTERED MENTAL STATUS, UNSPECIFIED  HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/27/2022 ALTERED MENTAL STATUS, UNSPECIFIED
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Aortic arteriosclerosis, Atrial fibrillation, Hypotension, Oesophageal achalasia
Clinical narrative: I95.9 HYPOTENSION 10/31/2022 ATRIAL FIBRILLATION, UNSPECIFIED I95.9 HYPOTENSION 10/31/2022 ATHEROSCLEROSIS OF AORTA I95.9 HYPOTENSION 10/31/2022 ACHALASIA
Age: 17.0
Sex: F
Vaccine: MENB
Symptoms: Erythema, Headache, Nasal congestion, Oropharyngeal pain, Pain
Clinical narrative: 5 hours after the vaccine was administered, she noticed arm redness and swelling on left arm. The next day, she had nasal congestion, sore throat, body aches, fever (101.0). Currently has body aches and a headache on 5/15/2023.
Age: 17.0
Sex: F
Vaccine: MENB
Symptoms: Peripheral swelling, Pyrexia
Clinical narrative: 5 hours after the vaccine was administered, she noticed arm redness and swelling on left arm. The next day, she had nasal congestion, sore throat, body aches, fever (101.0). Currently has body aches and a headache on 5/15/2023.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Audiogram abnormal, Deafness bilateral, Deafness neurosensory, Dizziness, Dizziness postural
Clinical narrative: I woke up at 2 AM on 10/23/2021 with severe vertigo; the room was spinning and I could not move my head without a feeling of dizziness and nausea.  Any time I attempted to move I felt as if I was going to either throw up or pass out.  After sitting on the bathroom floor for an hour I moved to sitting at the kitchen table with my head on the table.  I stayed there for the next several hours, covered in a blanket.  The sense of severe vertigo passed by 6 AM or so and I returned to bed.  I still had mild vertigo for about a week and this was then followed by mild ringing in my right ear which progressed to moderate ringing in both ears.  The bilateral tinnitus continues to this day.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Mobility decreased, Nausea, Sleep disorder, Tinnitus, Vertigo
Clinical narrative: I woke up at 2 AM on 10/23/2021 with severe vertigo; the room was spinning and I could not move my head without a feeling of dizziness and nausea.  Any time I attempted to move I felt as if I was going to either throw up or pass out.  After sitting on the bathroom floor for an hour I moved to sitting at the kitchen table with my head on the table.  I stayed there for the next several hours, covered in a blanket.  The sense of severe vertigo passed by 6 AM or so and I returned to bed.  I still had mild vertigo for about a week and this was then followed by mild ringing in my right ear which progressed to moderate ringing in both ears.  The bilateral tinnitus continues to this day.
Age: 2.0
Sex: M
Vaccine: COVID19-2, FLU4, HEP, HIBV, PNC13
Symptoms: Incorrect dose administered
Clinical narrative: Incorrect Moderna covid 19 vaccine strength  of vaccine given on April 28, 2023.  I called mom over the phone and requested she bring in child to vaccinate with correct dose.  Parent brought in child to vaccinate with correct Moderna vial vaccine and dose.
Age: 54.0
Sex: M
Vaccine: VARZOS
Symptoms: Rash, Rash erythematous, Rash papular, Rash pruritic
Clinical narrative: 2 weeks after vaccine rash, raised, red, itchy to arms spread over entire body- except for the hands, feet, neck, head.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Facial discomfort, Muscle tightness, Rash, Skin exfoliation
Clinical narrative: Face and neck tight, hot, itching, very red with small bumps under skin for several days followed by flaking and peeling of the skin ... this occurred within 48 hours of the vaccine and has been reoccurring approximately once a week ever since the vaccine with the flare up on May 13, 2023 being the 8th flare up.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Skin warm
Clinical narrative: Face and neck tight, hot, itching, very red with small bumps under skin for several days followed by flaking and peeling of the skin ... this occurred within 48 hours of the vaccine and has been reoccurring approximately once a week ever since the vaccine with the flare up on May 13, 2023 being the 8th flare up.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Epilepsy, Focal dyscognitive seizures, Gangrene, Hypertension, Hypoxia
Clinical narrative: Pfizer vaccine was administered outside of facility - reported by patient- ? NO LOT NUMBER WERE SUPPLIED ------------------------------------------------------------------------------------------------------------------------------- G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 SEVERE OBESITY EQUIVALENT, BMI 35-35.9, ADULT W CO-MORBIDITY G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 GANGRENE OF LEFT FOOT G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 GANGRENE OF RIGHT FOOT G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 HTN (HYPERTENSION) G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 HYPOXIA G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 NAUSEA AND VOMITING G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 SUBDURAL EMPYEMA
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Obesity, Status epilepticus, Subdural abscess, Vomiting
Clinical narrative: Pfizer vaccine was administered outside of facility - reported by patient- ? NO LOT NUMBER WERE SUPPLIED ------------------------------------------------------------------------------------------------------------------------------- G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 SEVERE OBESITY EQUIVALENT, BMI 35-35.9, ADULT W CO-MORBIDITY G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 GANGRENE OF LEFT FOOT G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 GANGRENE OF RIGHT FOOT G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 HTN (HYPERTENSION) G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 HYPOXIA G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 NAUSEA AND VOMITING G40.201 EPILEPSY, COMPLEX PARTIAL SEIZURES W STATUS EPILEPTICUS 11/3/2022 SUBDURAL EMPYEMA
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Chronic respiratory failure, Gastrooesophageal reflux disease, Hypoxia, Protein total abnormal
Clinical narrative: J96.00 ACUTE RESPIRATORY FAILURE 1/14/2022 ABNL PLASMA PROTEIN J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 ABNL PLASMA PROTEIN J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 11/3/2022 ABNL PLASMA PROTEIN J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 ABNL PLASMA PROTEIN R09.02 HYPOXIA 1/9/2022 ABNL PLASMA PROTEIN J96.00 ACUTE RESPIRATORY FAILURE 1/14/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 11/3/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) R09.02 HYPOXIA 1/9/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) J96.00 ACUTE RESPIRATORY FAILURE 1/14/2022 ALLERGIC RHINITIS J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 ALLERGIC RHINITIS J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 11/3/2022 ALLERGIC RHINITIS J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 ALLERGIC RHINITIS R09.02 HYPOXIA 1/9/2022 ALLERGIC RHINITIS
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Respiratory failure, Rhinitis allergic
Clinical narrative: J96.00 ACUTE RESPIRATORY FAILURE 1/14/2022 ABNL PLASMA PROTEIN J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 ABNL PLASMA PROTEIN J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 11/3/2022 ABNL PLASMA PROTEIN J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 ABNL PLASMA PROTEIN R09.02 HYPOXIA 1/9/2022 ABNL PLASMA PROTEIN J96.00 ACUTE RESPIRATORY FAILURE 1/14/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 11/3/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) R09.02 HYPOXIA 1/9/2022 GERD (GASTROESOPHAGEAL REFLUX DISEASE) J96.00 ACUTE RESPIRATORY FAILURE 1/14/2022 ALLERGIC RHINITIS J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 ALLERGIC RHINITIS J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 11/3/2022 ALLERGIC RHINITIS J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 1/10/2022 ALLERGIC RHINITIS R09.02 HYPOXIA 1/9/2022 ALLERGIC RHINITIS
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Atrial fibrillation, Oesophageal stenosis, Rectal prolapse, Shock
Clinical narrative: J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 11/19/2022 HX OF UPPER GASTROINTESTINAL BLEED R57.9 SHOCK, UNSPECIFIED 11/19/2022 HX OF UPPER GASTROINTESTINAL BLEED J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 11/19/2022 ATRIAL FIBRILLATION, PAROXYSMAL R57.9 SHOCK, UNSPECIFIED 11/19/2022 ATRIAL FIBRILLATION, PAROXYSMAL J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 11/19/2022 BENIGN ESOPHAGEAL STRICTURE R57.9 SHOCK, UNSPECIFIED 11/19/2022 BENIGN ESOPHAGEAL STRICTURE J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 11/19/2022 RECTAL PROLAPSE R57.9 SHOCK, UNSPECIFIED 11/19/2022 RECTAL PROLAPSE
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Chronic respiratory failure, Hypotension, Hypoxia, Pyrexia, Respiratory failure
Clinical narrative: Pfizer vaccine was administered outside of source - reported by patient- ? NO LOT NUMBER WERE SUPPLIED ------------------------------------------------------------------------------------------------------ I95.89 CHRONIC HYPOTENSION 3/10/2022 FEVER I95.9 HYPOTENSION 7/1/2022 FEVER J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 7/11/2022 FEVER R09.02 HYPOXIA 7/1/2022 FEVER
Age: 3.0
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event
Clinical narrative: no symptoms
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Chronic respiratory failure, Pulmonary hypertension, Respiratory failure
Clinical narrative: J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 5/2/2022 SECONDARY PULMONARY HTN
Age: 4.0
Sex: M
Vaccine: DTAP
Symptoms: Expired product administered, No adverse event
Clinical narrative: Expired DTAP vaccine administered. No effects yet noted. outcome unknown at this time.
Age: 90.0
Sex: M
Vaccine: COVID19-2
Symptoms: Acute kidney injury, Acute respiratory failure, Atrial fibrillation, Bradycardia, COVID-19
Clinical narrative: CLINICAL IMPRESSION: Altered mental status, COVID Hypoxia,  Chronic atrial fibrillation, Chronic kidney disease, unspecified CKD stage Came to ED for evaluation of altered mental status. Patient's wife died yesterday morning as well. Heart rate is elevated and variable, hx atrial fibrillation. Scattered rhonchi. Patient in the emergency department last night for epistaxis. Anticoagulated on Eliquis due to history of atrial fibrillation. A nasal packing was placed in the right nostril which remains in place currently.  Baseline use of O2- 1 to 2 L. Here he is requiring 3 to 4 L. On oxy mask rather than nasal cannula due to the presence of nasal packing.  Patient given dose of dexamethasone due to hypoxia in the presence of COVID. He was also given a dose of diltiazem due to elevated heart rate.  ASSESSMENT & PLAN: COVID c/b Hypoxia - Unclear day of symptom onset; PCR+ 5/9 - CXR - diffuse bilateral pulmonary infiltrates (but unchanged from 4/11) - Recently started wearing 2L O2 with activity - up to 5L in ED - wean as able - IV Decadron 10 mg x 3 days, then 6 mg x 7 days - Not a candidate for Remdesivir d/t borderline renal function, unclear onset - Mucinex BID - Isolation precautions Mon May 15 2023 Date of hospital admission: 5/9/2023 Date of death: 5/15/2023  Cause of death Interval 1. Acute hypoxic respiratory failure - 3 days 2. COVID-19 - 1 week  Admitted with: Altered Mental Status, COVID-19 pneumonia, metabolic encephalopathy, mild AKI. Hospital Course: Patient on nightly oxygen as he cannot tolerate CPAP. Patient lost his wife just day before admission. Patient started on remdesivir and dexamethasone for COVID-19. Patient is high aspiration risk and speech therapy evaluated on admission. Despite optimal treatment, patient started worsening and oxygenation got worse and he was transferred to ICU on 15 L / 90% Vapotherm. Patient started becoming more confused. Patient was started on high-dose steroids, low-dose Precedex drip. Patient continued to worsen. He removed his own oxygen and was noted to have severe bradycardia. Family was notified and worsening status was related. Patient was transitioned to hospice care on the night of 5/14/2023. Patient expired soon after at 0220 on 5/15 /2023. Family at bedside.  Submitter does not have access to further medical information on this case. If more information is needed, please contact the admitting hospital:
Age: 90.0
Sex: M
Vaccine: COVID19-2
Symptoms: COVID-19 pneumonia, Chest X-ray abnormal, Computerised tomogram head normal, Confusional state, Death
Clinical narrative: CLINICAL IMPRESSION: Altered mental status, COVID Hypoxia,  Chronic atrial fibrillation, Chronic kidney disease, unspecified CKD stage Came to ED for evaluation of altered mental status. Patient's wife died yesterday morning as well. Heart rate is elevated and variable, hx atrial fibrillation. Scattered rhonchi. Patient in the emergency department last night for epistaxis. Anticoagulated on Eliquis due to history of atrial fibrillation. A nasal packing was placed in the right nostril which remains in place currently.  Baseline use of O2- 1 to 2 L. Here he is requiring 3 to 4 L. On oxy mask rather than nasal cannula due to the presence of nasal packing.  Patient given dose of dexamethasone due to hypoxia in the presence of COVID. He was also given a dose of diltiazem due to elevated heart rate.  ASSESSMENT & PLAN: COVID c/b Hypoxia - Unclear day of symptom onset; PCR+ 5/9 - CXR - diffuse bilateral pulmonary infiltrates (but unchanged from 4/11) - Recently started wearing 2L O2 with activity - up to 5L in ED - wean as able - IV Decadron 10 mg x 3 days, then 6 mg x 7 days - Not a candidate for Remdesivir d/t borderline renal function, unclear onset - Mucinex BID - Isolation precautions Mon May 15 2023 Date of hospital admission: 5/9/2023 Date of death: 5/15/2023  Cause of death Interval 1. Acute hypoxic respiratory failure - 3 days 2. COVID-19 - 1 week  Admitted with: Altered Mental Status, COVID-19 pneumonia, metabolic encephalopathy, mild AKI. Hospital Course: Patient on nightly oxygen as he cannot tolerate CPAP. Patient lost his wife just day before admission. Patient started on remdesivir and dexamethasone for COVID-19. Patient is high aspiration risk and speech therapy evaluated on admission. Despite optimal treatment, patient started worsening and oxygenation got worse and he was transferred to ICU on 15 L / 90% Vapotherm. Patient started becoming more confused. Patient was started on high-dose steroids, low-dose Precedex drip. Patient continued to worsen. He removed his own oxygen and was noted to have severe bradycardia. Family was notified and worsening status was related. Patient was transitioned to hospice care on the night of 5/14/2023. Patient expired soon after at 0220 on 5/15 /2023. Family at bedside.  Submitter does not have access to further medical information on this case. If more information is needed, please contact the admitting hospital:
Age: 90.0
Sex: M
Vaccine: COVID19-2
Symptoms: Electrocardiogram abnormal, Epistaxis, General physical health deterioration, Heart rate increased, Hypoxia
Clinical narrative: CLINICAL IMPRESSION: Altered mental status, COVID Hypoxia,  Chronic atrial fibrillation, Chronic kidney disease, unspecified CKD stage Came to ED for evaluation of altered mental status. Patient's wife died yesterday morning as well. Heart rate is elevated and variable, hx atrial fibrillation. Scattered rhonchi. Patient in the emergency department last night for epistaxis. Anticoagulated on Eliquis due to history of atrial fibrillation. A nasal packing was placed in the right nostril which remains in place currently.  Baseline use of O2- 1 to 2 L. Here he is requiring 3 to 4 L. On oxy mask rather than nasal cannula due to the presence of nasal packing.  Patient given dose of dexamethasone due to hypoxia in the presence of COVID. He was also given a dose of diltiazem due to elevated heart rate.  ASSESSMENT & PLAN: COVID c/b Hypoxia - Unclear day of symptom onset; PCR+ 5/9 - CXR - diffuse bilateral pulmonary infiltrates (but unchanged from 4/11) - Recently started wearing 2L O2 with activity - up to 5L in ED - wean as able - IV Decadron 10 mg x 3 days, then 6 mg x 7 days - Not a candidate for Remdesivir d/t borderline renal function, unclear onset - Mucinex BID - Isolation precautions Mon May 15 2023 Date of hospital admission: 5/9/2023 Date of death: 5/15/2023  Cause of death Interval 1. Acute hypoxic respiratory failure - 3 days 2. COVID-19 - 1 week  Admitted with: Altered Mental Status, COVID-19 pneumonia, metabolic encephalopathy, mild AKI. Hospital Course: Patient on nightly oxygen as he cannot tolerate CPAP. Patient lost his wife just day before admission. Patient started on remdesivir and dexamethasone for COVID-19. Patient is high aspiration risk and speech therapy evaluated on admission. Despite optimal treatment, patient started worsening and oxygenation got worse and he was transferred to ICU on 15 L / 90% Vapotherm. Patient started becoming more confused. Patient was started on high-dose steroids, low-dose Precedex drip. Patient continued to worsen. He removed his own oxygen and was noted to have severe bradycardia. Family was notified and worsening status was related. Patient was transitioned to hospice care on the night of 5/14/2023. Patient expired soon after at 0220 on 5/15 /2023. Family at bedside.  Submitter does not have access to further medical information on this case. If more information is needed, please contact the admitting hospital:
Age: 90.0
Sex: M
Vaccine: COVID19-2
Symptoms: Intensive care, Lung infiltration, Mental status changes, Metabolic encephalopathy, Metabolic function test abnormal
Clinical narrative: CLINICAL IMPRESSION: Altered mental status, COVID Hypoxia,  Chronic atrial fibrillation, Chronic kidney disease, unspecified CKD stage Came to ED for evaluation of altered mental status. Patient's wife died yesterday morning as well. Heart rate is elevated and variable, hx atrial fibrillation. Scattered rhonchi. Patient in the emergency department last night for epistaxis. Anticoagulated on Eliquis due to history of atrial fibrillation. A nasal packing was placed in the right nostril which remains in place currently.  Baseline use of O2- 1 to 2 L. Here he is requiring 3 to 4 L. On oxy mask rather than nasal cannula due to the presence of nasal packing.  Patient given dose of dexamethasone due to hypoxia in the presence of COVID. He was also given a dose of diltiazem due to elevated heart rate.  ASSESSMENT & PLAN: COVID c/b Hypoxia - Unclear day of symptom onset; PCR+ 5/9 - CXR - diffuse bilateral pulmonary infiltrates (but unchanged from 4/11) - Recently started wearing 2L O2 with activity - up to 5L in ED - wean as able - IV Decadron 10 mg x 3 days, then 6 mg x 7 days - Not a candidate for Remdesivir d/t borderline renal function, unclear onset - Mucinex BID - Isolation precautions Mon May 15 2023 Date of hospital admission: 5/9/2023 Date of death: 5/15/2023  Cause of death Interval 1. Acute hypoxic respiratory failure - 3 days 2. COVID-19 - 1 week  Admitted with: Altered Mental Status, COVID-19 pneumonia, metabolic encephalopathy, mild AKI. Hospital Course: Patient on nightly oxygen as he cannot tolerate CPAP. Patient lost his wife just day before admission. Patient started on remdesivir and dexamethasone for COVID-19. Patient is high aspiration risk and speech therapy evaluated on admission. Despite optimal treatment, patient started worsening and oxygenation got worse and he was transferred to ICU on 15 L / 90% Vapotherm. Patient started becoming more confused. Patient was started on high-dose steroids, low-dose Precedex drip. Patient continued to worsen. He removed his own oxygen and was noted to have severe bradycardia. Family was notified and worsening status was related. Patient was transitioned to hospice care on the night of 5/14/2023. Patient expired soon after at 0220 on 5/15 /2023. Family at bedside.  Submitter does not have access to further medical information on this case. If more information is needed, please contact the admitting hospital:
Age: 90.0
Sex: M
Vaccine: COVID19-2
Symptoms: Nasal cavity packing, Renal impairment, Rhonchi, SARS-CoV-2 test positive
Clinical narrative: CLINICAL IMPRESSION: Altered mental status, COVID Hypoxia,  Chronic atrial fibrillation, Chronic kidney disease, unspecified CKD stage Came to ED for evaluation of altered mental status. Patient's wife died yesterday morning as well. Heart rate is elevated and variable, hx atrial fibrillation. Scattered rhonchi. Patient in the emergency department last night for epistaxis. Anticoagulated on Eliquis due to history of atrial fibrillation. A nasal packing was placed in the right nostril which remains in place currently.  Baseline use of O2- 1 to 2 L. Here he is requiring 3 to 4 L. On oxy mask rather than nasal cannula due to the presence of nasal packing.  Patient given dose of dexamethasone due to hypoxia in the presence of COVID. He was also given a dose of diltiazem due to elevated heart rate.  ASSESSMENT & PLAN: COVID c/b Hypoxia - Unclear day of symptom onset; PCR+ 5/9 - CXR - diffuse bilateral pulmonary infiltrates (but unchanged from 4/11) - Recently started wearing 2L O2 with activity - up to 5L in ED - wean as able - IV Decadron 10 mg x 3 days, then 6 mg x 7 days - Not a candidate for Remdesivir d/t borderline renal function, unclear onset - Mucinex BID - Isolation precautions Mon May 15 2023 Date of hospital admission: 5/9/2023 Date of death: 5/15/2023  Cause of death Interval 1. Acute hypoxic respiratory failure - 3 days 2. COVID-19 - 1 week  Admitted with: Altered Mental Status, COVID-19 pneumonia, metabolic encephalopathy, mild AKI. Hospital Course: Patient on nightly oxygen as he cannot tolerate CPAP. Patient lost his wife just day before admission. Patient started on remdesivir and dexamethasone for COVID-19. Patient is high aspiration risk and speech therapy evaluated on admission. Despite optimal treatment, patient started worsening and oxygenation got worse and he was transferred to ICU on 15 L / 90% Vapotherm. Patient started becoming more confused. Patient was started on high-dose steroids, low-dose Precedex drip. Patient continued to worsen. He removed his own oxygen and was noted to have severe bradycardia. Family was notified and worsening status was related. Patient was transitioned to hospice care on the night of 5/14/2023. Patient expired soon after at 0220 on 5/15 /2023. Family at bedside.  Submitter does not have access to further medical information on this case. If more information is needed, please contact the admitting hospital:
Age: 69.0
Sex: F
Vaccine: COVID19-2
Symptoms: Benign breast neoplasm, COVID-19, Headache, Hypersomnia, Impaired work ability
Clinical narrative: In December 2022, I got very sleepy and slept a lot. I had a lot of headaches and a fever. I took a home antigen test and got a positive result. I was sick for about ten days. I called my doctor, who offered medication, but I refused it. I also did not take any OTC medicines or herbal remedies. I just basically slept a lot, and that was how I managed my illness. I eventually took another test and got a negative result. Altogether, I was out of work for ten days. I felt better after the ten days were up. A few months after this happened, I underwent a mammogram, and it was discovered that I had lumps in the left breast. I was told that the lumps were benign and probably the result of the vaccine. This was not this first time this had happened, because after I got my first dose of COVID-19 vaccine, I developed lumps in my right breast and in my neck. The lump in the neck lasted for about three months. I underwent a mammogram and a biopsy of the lump in the breast. They weren't cancerous, but they were enlarged nodules, and the doctors believed they may have been caused by the COVID-19 vaccine. The lump in the neck eventually went away, but I think I still have the lumps in the right breast, because when I underwent another mammogram, they were detected. However, the doctors did not think it was necessary to conduct another biopsy. After I got my second dose of COVID-19 vaccine, I had lumps in the left breast. The lumps hurt a little. I believe the lumps in the left breast are also still present, since they were detected in my last mammogram. My doctors have told me that I need to undergo a mammogram every six months to make sure that the enlarged nodules have not turned cancerous.
Age: 69.0
Sex: F
Vaccine: COVID19-2
Symptoms: Lymphadenopathy, Malaise, Pyrexia, SARS-CoV-2 test positive, Somnolence
Clinical narrative: In December 2022, I got very sleepy and slept a lot. I had a lot of headaches and a fever. I took a home antigen test and got a positive result. I was sick for about ten days. I called my doctor, who offered medication, but I refused it. I also did not take any OTC medicines or herbal remedies. I just basically slept a lot, and that was how I managed my illness. I eventually took another test and got a negative result. Altogether, I was out of work for ten days. I felt better after the ten days were up. A few months after this happened, I underwent a mammogram, and it was discovered that I had lumps in the left breast. I was told that the lumps were benign and probably the result of the vaccine. This was not this first time this had happened, because after I got my first dose of COVID-19 vaccine, I developed lumps in my right breast and in my neck. The lump in the neck lasted for about three months. I underwent a mammogram and a biopsy of the lump in the breast. They weren't cancerous, but they were enlarged nodules, and the doctors believed they may have been caused by the COVID-19 vaccine. The lump in the neck eventually went away, but I think I still have the lumps in the right breast, because when I underwent another mammogram, they were detected. However, the doctors did not think it was necessary to conduct another biopsy. After I got my second dose of COVID-19 vaccine, I had lumps in the left breast. The lumps hurt a little. I believe the lumps in the left breast are also still present, since they were detected in my last mammogram. My doctors have told me that I need to undergo a mammogram every six months to make sure that the enlarged nodules have not turned cancerous.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Bile duct stone, Chronic kidney disease, Glomerular filtration rate, Hyperkalaemia, Myocardial ischaemia
Clinical narrative: Pfizer vaccine was administered outside of clinic- reported by patient- ? NO LOT NUMBER WERE SUPPLIED ---------------------------------------------------------------------------------------------------------------------------------  DEMAND ISCHEMIA 9/3/2022 HYPERKALEMIA  DEMAND ISCHEMIA 9/3/2022 CKD STAGE 4 (GFR 15-29)  DEMAND ISCHEMIA 9/3/2022 CHOLEDOCHOLITHIASIS
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Hiatus hernia
Clinical narrative: ACUTE RESPIRATORY FAILURE 1/5/2022 HIATAL HERNIA
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: Atrial fibrillation, Dyskinesia oesophageal, Dysphagia, Femoral neck fracture, Hypoxia
Clinical narrative: HYPOXIA 4/17/2022 ATRIAL FIBRILLATION, UNSPECIFIED HYPOXIA 4/17/2022 DYSPHAGIA    ESOPHAGEAL DYSKINESIA HYPOXIA 4/17/2022 RIGHT FEMORAL NECK GARDEN 1 FX INIT
Sex: F
Vaccine: HPV9
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: she initially receive her 1st dose in "April 2021" however, she had forgotten about the follow up doses, and "started over" again in October 2022. In October 2022 she received her "first dose" again, and receiver her "second dose" in December 2022.; No additional adverse effects reported; This spontaneous report was received from a female patient of unknown age, referring to herself.  The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On an unknown date in April 2021, the patient was vaccinated with the first dose of  hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, 1st dose, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided).  However, she had forgotten about the follow up doses, and "started over" again in October 2022. In October 2022 she received her "first dose" again, and receiver her "second dose" in December 2022. She reported that she was on track to finishing her dosage series this month (Inappropriate schedule of product administration). No additional adverse effects or details reported.
Age: 1.0
Sex: M
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE reported; temperature excursion and administered to patient; This spontaneous report was received from a medical assistant referring to a 12-month-old male patient. Information of the patient's pertinent medical history, concomitant therapy, concurrent condition and drug reactions/allergies was not reported.  On 07-FEB-2023, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) injection (lot# W006412, expiration date upon internal review was established as 23-FEB-2024, dose and strength were not reported) intramuscularly in right thigh for prophylaxis at a private doctor's office/hospital, after a temperature excursion. Total time in the range of -14 degree Celsius to -10 degree Celsius was 1 hour. Total combined excursion time was 1 hour (product storage error). This adverse event was previously reported to manufacturer. No additional adverse events were provided (no adverse event).  This is one of several reports reported by the same reporter.; Sender's Comments:  US-009507513-2304USA007931: US-009507513-2303USA002114:
Age: 74.0
Sex: M
Vaccine: HEP, HEPA
Symptoms: No adverse event, Product preparation error, Underdose
Clinical narrative: No additional AE; received the pediatric 0.5 ml dose of the vaccine instead of the adult 1.0 ml dose.; Product preparation error; This spontaneous report was received from a nurse and refers to a 74-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 04-APR-2023, the patient was vaccinated with hepatitis b vaccine (recombinant) (RECOMBIVAX HB), 0.5 milliliters (ml) (pediatric dose) (lot #, expiry date, and route of administration were not provided) as prophylaxis (also reported as hepatitis a vaccine, inactivated (VAQTA), 0.5 ml, lot #W028555, expiration date: 10-JUL-2024, administered intramuscularly in the right deltoid for prophylaxis; conflicting information). It was reported that the error occurred during the preparation and the administration of the product (underdose, product preparation error).   No additional adverse event was reported (no adverse event).   This is one of two reports received from the same reporter. ; Sender's Comments:  US-009507513-2305USA000825:
Age: 1.0
Sex: U
Vaccine: VARCEL
Symptoms: Accidental underdose, No adverse event
Clinical narrative: No additional AEs were reported; patient received smaller than recommended dose of VARIVAX due to the needle being slipped out of the patient due to a human error; This spontaneous report has been received from nurse concerning a 12-month-old patient of unknown gender. Their concurrent conditions, medical history, drug reactions/allergies, and concomitant medications were not provided.   On 28-OCT-2022, the patient was vaccinated with a dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) administered as prophylaxis, lot number w018831 with expiration date 14-JUN-2024 (dosage regimen and route of administration were not provided). According to the reporter, the patient received a "smaller" than recommended dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) since the needle slipped out of the patient due to human error (Accidental underdose). No additional adverse event was reported (No adverse event).
Sex: U
Vaccine: VARCEL
Symptoms: Product storage error
Clinical narrative: No additional AEs; Temperature excursion for VARIVAX. Product was administered; This spontaneous report has been received from an office manager and refers to a patient of unknown age and gender.  The patient's pertinent medical history, other drug reactions or allergies, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with a varicella virus vaccine live (oka/merck) (VARIVAX), injection, that had suffered a temperature excursion (product storage issue) (lot number W025277 has been verified to be a valid lot number for varicella virus vaccine live (oka/merck) (VARIVAX), expiration date has been established as 10-AUG-2024), administered for prophylaxis (strength, and route of administration were not provided).
Sex: U
Vaccine: HPV9
Symptoms: Product storage error
Clinical narrative: No additional AE/PQC reported; GARDASIL 9 was administered on 5/8/2023.; This spontaneous report was received from a nurse prescriber and refers to a patient of unknown age and gender. No information about the patient's pertinent medical history, concurrent conditions, concomitant medications and drug reactions or allergies was provided.  On 08-MAY-2023, the patient was vaccinated with a dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) lot # W015188 with expiration date of 06-JAN-2025, for prophylaxis (route of administration was not reported), that had a temperature excursion (product storage error). Hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was supported after being evaluated. No additional event reported.   The vaccine underwent in temperature excursion of 10.7C, time frame 2 hours 10 minutes 0 seconds, no previous temperature excursion occurred.   No further clarify.
Sex: M
Vaccine: VARZOS
Symptoms: Altered state of consciousness, Bladder catheterisation, Blood test, CSF test, Cardiac monitoring
Clinical narrative: extensive longitudinal acute transverse myelitis, there is a possible argument that can be made of the link between the patient's acute transverse myelitis (ATM) and the Shingles vaccine; pulseless ventricular tachycardia, it is possible that our patient's ventricular tachycardia could also be related to the Shingles vaccine; This literature marketed report has been received from the authors of a published article, titled as stated below, and refers to a 50-year-old male patient. His concurrent conditions included psoriatic arthritis. Concomitant medications included methotrexate.  On an unknown date, the patient was vaccinated with zoster vaccine live (manufacturer unknown) subcutaneous injection (exact dose, route of administration, anatomical site, lot # and expiration date were not provided) as prophylaxis.  On an unknown date (reported as "one week following a shingles vaccine"), the patient presented to the emergency room (ER) with complaint of ascending bilateral lower extremity paresthesia. The paresthesia progressed from his feet to groin with associated loss of sensation with urination, incomplete bladder emptying, and ambulatory dysfunction due to difficulty with proprioception of both his legs. Examination was significant for diminished light touch, vibration, and temperature sensation of the bilateral lower extremities. Urinary retention was noted and was treated with a foley catheter. Magnetic resonance imaging (MRI) of the patient's spine revealed longitudinally extensive T2 hyperintensity from the lower cervical spine to the upper thoracic spine. The patient's ER course was complicated by acute onset of diaphoresis and lightheadedness followed by a syncopal episode. The patient was unresponsive and pulseless, and the telemetry was consistent ventricular tachycardia which was quickly self-limiting with return of mental awareness and normal sinus rhythm. Amiodarone was initiated and the patient remained in normal sinus rhythm. He was treated with 1 g of intravenous (IV) solumedrol for suspected extensive longitudinal acute transverse myelitis (ATM) based on clinical presentation and spinal cord appearance on MRI. After 5 days of IV steroid treatment, there was no clinical improvement and the decision was made to initiate plasmapheresis, which was well tolerated and the patient's symptoms gradually improved. Extensive blood work and cerebrospinal fluid (CSF) studies failed to determine the etiology of the ATM. The patient's symptoms continued to progress (not recovered), and on an unknown date, he was discharged to a rehab facility with long-term cardiac event monitoring.  The reporter considered myelitis transverse and ventricular tachycardia to be possibly related to zoster vaccine live (manufacturer unknown).  Upon internal review, the events of myelitis transverse and ventricular tachycardia were determined to be medically significant.  Literature Report:
Sex: M
Vaccine: VARZOS
Symptoms: Cardiac telemetry abnormal, Decreased vibratory sense, Dizziness, Electrocardiogram ambulatory, Gait disturbance
Clinical narrative: extensive longitudinal acute transverse myelitis, there is a possible argument that can be made of the link between the patient's acute transverse myelitis (ATM) and the Shingles vaccine; pulseless ventricular tachycardia, it is possible that our patient's ventricular tachycardia could also be related to the Shingles vaccine; This literature marketed report has been received from the authors of a published article, titled as stated below, and refers to a 50-year-old male patient. His concurrent conditions included psoriatic arthritis. Concomitant medications included methotrexate.  On an unknown date, the patient was vaccinated with zoster vaccine live (manufacturer unknown) subcutaneous injection (exact dose, route of administration, anatomical site, lot # and expiration date were not provided) as prophylaxis.  On an unknown date (reported as "one week following a shingles vaccine"), the patient presented to the emergency room (ER) with complaint of ascending bilateral lower extremity paresthesia. The paresthesia progressed from his feet to groin with associated loss of sensation with urination, incomplete bladder emptying, and ambulatory dysfunction due to difficulty with proprioception of both his legs. Examination was significant for diminished light touch, vibration, and temperature sensation of the bilateral lower extremities. Urinary retention was noted and was treated with a foley catheter. Magnetic resonance imaging (MRI) of the patient's spine revealed longitudinally extensive T2 hyperintensity from the lower cervical spine to the upper thoracic spine. The patient's ER course was complicated by acute onset of diaphoresis and lightheadedness followed by a syncopal episode. The patient was unresponsive and pulseless, and the telemetry was consistent ventricular tachycardia which was quickly self-limiting with return of mental awareness and normal sinus rhythm. Amiodarone was initiated and the patient remained in normal sinus rhythm. He was treated with 1 g of intravenous (IV) solumedrol for suspected extensive longitudinal acute transverse myelitis (ATM) based on clinical presentation and spinal cord appearance on MRI. After 5 days of IV steroid treatment, there was no clinical improvement and the decision was made to initiate plasmapheresis, which was well tolerated and the patient's symptoms gradually improved. Extensive blood work and cerebrospinal fluid (CSF) studies failed to determine the etiology of the ATM. The patient's symptoms continued to progress (not recovered), and on an unknown date, he was discharged to a rehab facility with long-term cardiac event monitoring.  The reporter considered myelitis transverse and ventricular tachycardia to be possibly related to zoster vaccine live (manufacturer unknown).  Upon internal review, the events of myelitis transverse and ventricular tachycardia were determined to be medically significant.  Literature Report:
Sex: M
Vaccine: VARZOS
Symptoms: Hyperhidrosis, Loss of bladder sensation, Loss of proprioception, Magnetic resonance imaging spinal abnormal, Myelitis transverse
Clinical narrative: extensive longitudinal acute transverse myelitis, there is a possible argument that can be made of the link between the patient's acute transverse myelitis (ATM) and the Shingles vaccine; pulseless ventricular tachycardia, it is possible that our patient's ventricular tachycardia could also be related to the Shingles vaccine; This literature marketed report has been received from the authors of a published article, titled as stated below, and refers to a 50-year-old male patient. His concurrent conditions included psoriatic arthritis. Concomitant medications included methotrexate.  On an unknown date, the patient was vaccinated with zoster vaccine live (manufacturer unknown) subcutaneous injection (exact dose, route of administration, anatomical site, lot # and expiration date were not provided) as prophylaxis.  On an unknown date (reported as "one week following a shingles vaccine"), the patient presented to the emergency room (ER) with complaint of ascending bilateral lower extremity paresthesia. The paresthesia progressed from his feet to groin with associated loss of sensation with urination, incomplete bladder emptying, and ambulatory dysfunction due to difficulty with proprioception of both his legs. Examination was significant for diminished light touch, vibration, and temperature sensation of the bilateral lower extremities. Urinary retention was noted and was treated with a foley catheter. Magnetic resonance imaging (MRI) of the patient's spine revealed longitudinally extensive T2 hyperintensity from the lower cervical spine to the upper thoracic spine. The patient's ER course was complicated by acute onset of diaphoresis and lightheadedness followed by a syncopal episode. The patient was unresponsive and pulseless, and the telemetry was consistent ventricular tachycardia which was quickly self-limiting with return of mental awareness and normal sinus rhythm. Amiodarone was initiated and the patient remained in normal sinus rhythm. He was treated with 1 g of intravenous (IV) solumedrol for suspected extensive longitudinal acute transverse myelitis (ATM) based on clinical presentation and spinal cord appearance on MRI. After 5 days of IV steroid treatment, there was no clinical improvement and the decision was made to initiate plasmapheresis, which was well tolerated and the patient's symptoms gradually improved. Extensive blood work and cerebrospinal fluid (CSF) studies failed to determine the etiology of the ATM. The patient's symptoms continued to progress (not recovered), and on an unknown date, he was discharged to a rehab facility with long-term cardiac event monitoring.  The reporter considered myelitis transverse and ventricular tachycardia to be possibly related to zoster vaccine live (manufacturer unknown).  Upon internal review, the events of myelitis transverse and ventricular tachycardia were determined to be medically significant.  Literature Report: